Sacubitril/Valsartan versus enalapril in nonischemic heart failure in Paradigm-Hf trial
Journal Title: Journal of Cardiovascular Medicine and Cardiology - Year 2018, Vol 5, Issue 4
Abstract
Background: We compared the angiotensin receptor–neprilysin inhibitor LCZ696 (sacubitril/valsartan) with enalapril in patients who had nonischemic heart failure with a reduced ejection fraction. Methods: In this double-blind trial, we randomly assigned 8442 patients with class II, III, or IV heart failure and an ejection fraction of 40% or less to receive either LCZ696 (at a dose of 200 mg twice daily) or enalapril (at a dose of 10 mg twice daily), in addition to recommended therapy. The primary outcome was a composite of death from cardiovascular causes or hospitalization for heart failure, but the trial was designed to detect a difference in the rates of death from cardiovascular causes. Results: The trial was stopped early, according to pre specified rules, after a median follow up of 27 months, because the boundary for an overwhelming benefit with LCZ696 had been crossed. The ischemic patients were 5036 (60%) patients and non-ischemic patients were 3363 (40%) patients. In ischemic and in non-ischemic group the LCZ696 was superior to enalapril for reduce primary outcome and CV death (P< 0.001). In LCZ696 group: the primary outcome had occurred in 339 patients (20.16 %) in the non-ischemic group and 575 patients (22.9 %) in the ischemic group (P: 0.03). A total of 199 patients (11.8%) in non-ischemic group and 359 patients in ischemic group (14.3%) died from cardiovascular causes (P: 0.01). and no significant difference between in CV death and primary outcome in enalapril group in the ischemic and non-ischemic patients Conclusions: LCZ696 was superior to enalapril in reducing the risks of cardiovascular death and hospitalization for heart failure in ischemic and non-ischemic heart failure.
Authors and Affiliations
Habib Mohammed
Keywords
Related Articles
- EP ID EP523879
- DOI 10.17352/2455-2976.000070
- Views 82
- Downloads 0
Lactate Dehydrogenase is involved in but not the Target Antigen in Children with Kawasaki Disease
Background: Kawasaki disease (KD) is an acute vasculitis often complicating coronary arterial lesions, and gradually becomes the leading cause of acquired heart disease instead of rheumatism. Previous studies often regar...
Sacubitril/Valsartan versus enalapril in nonischemic heart failure in Paradigm-Hf trial
Background: We compared the angiotensin receptor–neprilysin inhibitor LCZ696 (sacubitril/valsartan) with enalapril in patients who had nonischemic heart failure with a reduced ejection fraction. Methods: In this double-...
Large Thrombotic Coronary Artery Aneurysm Treated With a Covered Stent Using OCT for Procedural Guidance
Coronary artery aneurysm (CAA) is an uncommon finding in patients undergoing a coronary angiography, with an incidence of less than 5% [1]. CAA is defined as coronary dilation of more than 1,5 times the adjacent vessel d...
Combined Application of Percutaneous Extracorporeal Lung Assistance System Together with Catheter-Directed Therapy for the Rescue of Massive Pulmonary Embolism after Failed Systemic Thrombolysis
A 56 year-old, formerly healthy man, who had undergone surgery of the shoulder joint earlier that same day, was presented at our department with a sudden onset of severe dyspnea and thoracic pain. Clinical findings were...
Exercise Echocardiography in Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy (HCM) is a relatively frequent genetic disease that affects 1/500 human beings. Main problems with this disease are the development of symptoms in 10-20% of affected individuals, and the incre...